Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis

F. Salerno, P. Incerti, S. Badalamenti, E. Lorenzano, G. Graziani, A. Morganti, P. Ghirardi

Research output: Contribution to journalArticle

Abstract

We investigated the renal and humoral effects of short-term administration of ibopamine, an orally active dopamine agonist, in patients with liver cirrhosis. The patients were divided into two groups on the basis of sodium excretion with a constant sodium intake of 40 mEq/d. We also compared the effects of ibopamine with those induced by intravenous infusion of dopamine hydrochloride (3 μg/kg per minute) in similar patients. Ibopamine caused significant increases in urine output, glomerular filtration rate, and sodium excretion throughout the 4 hours of the trial in patients with basal sodium excretion rate greater than 20 mmol/d. These renal effects were associated with a significant reduction in plasma aldosterone concentration. In contrast, only a transient increase in glomerular filtration and a dilution in plasma aldosterone concentration were observed after ibopamine in the patients with a basal sodium excretion rate less than 20 mmol/d. The infusion of dopamine had renal effects similar to those of ibopamine in both groups of patients. These results indicate that in cirrhotic patients with normal sodium excretion, ibopamine exerts a diuretic and natriuretic effect similar to that of dopamine infusion. However, these properties of dopaminergic agents are apparently lost in patients with avid sodium retention.

Original languageEnglish
Pages (from-to)65-69
Number of pages5
JournalArchives of Internal Medicine
Volume150
Issue number1
DOIs
Publication statusPublished - 1990

Fingerprint

Dopamine Agonists
Liver Cirrhosis
Kidney
Sodium
Dopamine
Aldosterone
Natriuretic Agents
Dopamine Agents
ibopamine
Glomerular Filtration Rate
Diuretics
Intravenous Infusions
Urine

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis. / Salerno, F.; Incerti, P.; Badalamenti, S.; Lorenzano, E.; Graziani, G.; Morganti, A.; Ghirardi, P.

In: Archives of Internal Medicine, Vol. 150, No. 1, 1990, p. 65-69.

Research output: Contribution to journalArticle

Salerno, F. ; Incerti, P. ; Badalamenti, S. ; Lorenzano, E. ; Graziani, G. ; Morganti, A. ; Ghirardi, P. / Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis. In: Archives of Internal Medicine. 1990 ; Vol. 150, No. 1. pp. 65-69.
@article{17667014e4cb4f7fa926c6bf6434242c,
title = "Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis",
abstract = "We investigated the renal and humoral effects of short-term administration of ibopamine, an orally active dopamine agonist, in patients with liver cirrhosis. The patients were divided into two groups on the basis of sodium excretion with a constant sodium intake of 40 mEq/d. We also compared the effects of ibopamine with those induced by intravenous infusion of dopamine hydrochloride (3 μg/kg per minute) in similar patients. Ibopamine caused significant increases in urine output, glomerular filtration rate, and sodium excretion throughout the 4 hours of the trial in patients with basal sodium excretion rate greater than 20 mmol/d. These renal effects were associated with a significant reduction in plasma aldosterone concentration. In contrast, only a transient increase in glomerular filtration and a dilution in plasma aldosterone concentration were observed after ibopamine in the patients with a basal sodium excretion rate less than 20 mmol/d. The infusion of dopamine had renal effects similar to those of ibopamine in both groups of patients. These results indicate that in cirrhotic patients with normal sodium excretion, ibopamine exerts a diuretic and natriuretic effect similar to that of dopamine infusion. However, these properties of dopaminergic agents are apparently lost in patients with avid sodium retention.",
author = "F. Salerno and P. Incerti and S. Badalamenti and E. Lorenzano and G. Graziani and A. Morganti and P. Ghirardi",
year = "1990",
doi = "10.1001/archinte.150.1.65",
language = "English",
volume = "150",
pages = "65--69",
journal = "Archives of Internal Medicine",
issn = "0003-9926",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis

AU - Salerno, F.

AU - Incerti, P.

AU - Badalamenti, S.

AU - Lorenzano, E.

AU - Graziani, G.

AU - Morganti, A.

AU - Ghirardi, P.

PY - 1990

Y1 - 1990

N2 - We investigated the renal and humoral effects of short-term administration of ibopamine, an orally active dopamine agonist, in patients with liver cirrhosis. The patients were divided into two groups on the basis of sodium excretion with a constant sodium intake of 40 mEq/d. We also compared the effects of ibopamine with those induced by intravenous infusion of dopamine hydrochloride (3 μg/kg per minute) in similar patients. Ibopamine caused significant increases in urine output, glomerular filtration rate, and sodium excretion throughout the 4 hours of the trial in patients with basal sodium excretion rate greater than 20 mmol/d. These renal effects were associated with a significant reduction in plasma aldosterone concentration. In contrast, only a transient increase in glomerular filtration and a dilution in plasma aldosterone concentration were observed after ibopamine in the patients with a basal sodium excretion rate less than 20 mmol/d. The infusion of dopamine had renal effects similar to those of ibopamine in both groups of patients. These results indicate that in cirrhotic patients with normal sodium excretion, ibopamine exerts a diuretic and natriuretic effect similar to that of dopamine infusion. However, these properties of dopaminergic agents are apparently lost in patients with avid sodium retention.

AB - We investigated the renal and humoral effects of short-term administration of ibopamine, an orally active dopamine agonist, in patients with liver cirrhosis. The patients were divided into two groups on the basis of sodium excretion with a constant sodium intake of 40 mEq/d. We also compared the effects of ibopamine with those induced by intravenous infusion of dopamine hydrochloride (3 μg/kg per minute) in similar patients. Ibopamine caused significant increases in urine output, glomerular filtration rate, and sodium excretion throughout the 4 hours of the trial in patients with basal sodium excretion rate greater than 20 mmol/d. These renal effects were associated with a significant reduction in plasma aldosterone concentration. In contrast, only a transient increase in glomerular filtration and a dilution in plasma aldosterone concentration were observed after ibopamine in the patients with a basal sodium excretion rate less than 20 mmol/d. The infusion of dopamine had renal effects similar to those of ibopamine in both groups of patients. These results indicate that in cirrhotic patients with normal sodium excretion, ibopamine exerts a diuretic and natriuretic effect similar to that of dopamine infusion. However, these properties of dopaminergic agents are apparently lost in patients with avid sodium retention.

UR - http://www.scopus.com/inward/record.url?scp=0025261836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025261836&partnerID=8YFLogxK

U2 - 10.1001/archinte.150.1.65

DO - 10.1001/archinte.150.1.65

M3 - Article

C2 - 1967522

AN - SCOPUS:0025261836

VL - 150

SP - 65

EP - 69

JO - Archives of Internal Medicine

JF - Archives of Internal Medicine

SN - 0003-9926

IS - 1

ER -